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Abstract
Although highly active antiretroviral therapies (HAART) remarkably increased life expec-
tancy of HIV positive people, the rate of novel HIV-1 infections worldwide still represent a
major concern. In this context, pre-exposure prophylaxis (PrEP) approaches such as vagi-
nal microbicide gels topically releasing antiretroviral drugs, showed to have a striking impact
in limiting HIV-1 spread. Nevertheless, the co-presence of other genital infections, particu-
larly those due to HSV-1 or 2, constitute a serious drawback that strongly limits the efficacy
of PrEP approaches. For this reason, combinations of different compounds with mixed anti-
viral and antiretroviral activity are thoroughly investigated Here we report the synthesis and
the biological evaluation of a novel series of rhodanine derivatives, which showed to inhibit
both HIV-1 and HSV-1/2 replication at nanomolar concentration, and were found to be active
also on acyclovir resistant HSV-2 strains. The compounds showed a considerable reduction
of activity in presence of serum due to a high binding to serum albumin, as determined
through in vitro ADME evaluations. However, the most promising compound of the series
maintained a considerable activity in gel formulation, with an EC50 comparable to that
obtained for the reference drug tenofovir. Moreover, the series of compounds showed phar-
macokinetic properties suitable for topical formulation, thus suggesting that the novel rhoda-
nine derivatives could represent effective agents to be used as dual anti HIV/HSV
microbicides in PrEP approaches.
Introduction
Implementation of extensive patients’ treatment and prevention strategies in the global
response against human immunodeficiency virus type 1 (HIV-1) epidemic has resulted in
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significant reduction of new infections worldwide. Nevertheless, sexually transmitted infec-
tions (STIs), including HIV-1, represent a major global burden, particularly in resource lim-
ited regions [1]. Moreover, since 2010, no significant reduction of novel HIV-1 infections was
recoded in most countries, suggesting that current efforts, including the increase access to
antiretroviral treatment are not sufficient to end the AIDS epidemic.
Microbicides delivering antiviral compounds in the vagina, in the rectum or in the oral cav-
ity, were shown to reduce HIV-1 transmission and can thus be considered effective tools to
implement the global response to HIV-1. In fact, the CAPRISA 004 trial showed that 1% teno-
fovir (TFV) microbicide vaginal gel used as pre-exposure prophylaxis (PrEP) approach showed
a 39% reduction of infection risk, demonstrating that topically used drugs can have a huge
impact in limiting HIV-1 spread [2–7]. However, efficacy of currently planned PrEP
approaches may be hampered by the presence of circulating strains already resistant to avail-
able antiretroviral agents (present in the PrEP preparations) or the co-presence of other genital
infections that increase patient’s susceptibility to HIV-1 infection [8–11]. This is the case of
genital infections caused by herpes simplex virus type 2 (and type-1 in fraction of genital infec-
tions). In some regions, especially in those with the highest prevalence of HIV-1 infection,
such as in many African countries, up to 80% of young adults are serum-positive for genital
herpes infection, with a significant fraction of herpes virus recurrences [12–15]. All currently
available PrEP approaches, including vaginal gels containing antiretroviral or intravaginal
rings with long-acting antiretroviral drugs or implantable and injectable formulations, selec-
tively inhibit HIV-1 replication but have no or very limited activity against HSV-1 or 2 [16]
thus their efficacy may be limited or not sufficient to prevent new infections especially in high
prevalence settings for both viral infections. In our previous papers [17–19], we demonstrated
that these molecules block very early step in HIV-1 replication, preventing viral entry into
cells. This may be relevant to increase bioavailability of antiretroviral agents in topical prepara-
tions. In fact, almost all currently available PrEP approaches target intracellular steps of virus
replication, suggesting that available drugs will have to penetrate both the mucosal barrier and
the target cell membranes in order to be effective when used in topical preparations. During
the screening of our in house library against a panel of sexually transmitted viruses, we surpris-
ingly found that compounds 1 and 2 (Fig 1) [17–19], potently inhibited the replication of both
HSV-1 and HSV-2, without any antiviral activity on HPV-16, a not enveloped virus particu-
larly relevant in sexually transmitted infections. As a continuation of our previous work, a
novel series of rhodanine derivatives was synthesized. Biological evaluation showed that these
compounds are able to inhibit HIV-1 and HSV-1 and 2 replication at nanomolar concentra-
tion. We also characterized the binding affinity of these molecules to human albumin and
their efficacy as antiviral agents in prototypical genital PrEP gel preparations. Furthermore, a
preliminary ADME evaluation was performed by determining water solubility, passive mem-
brane permeability and metabolic stability of selected derivatives.
Results and discussion
Chemistry
As shown in Fig 2, the synthetic route to the final compounds 9a-f first entailed the prepara-
tion of the target acid 6. Methyl 4-(5-formylfuran-2-yl)-2-hydroxybenzoate (5) was obtained
through Suzuki reaction between commercially available 3 (methyl 4-iodosalicylate) and com-
pound 4 (5-formyl-2-furanylboronic acid), subsequent basic hydrolysis furnished the acid ana-
logue (6). Derivatives 9a-f, were synthesized using a recently published [18] multicomponent
protocol that includes nucleophilic displacement between the opportune amine and
Rhodanine derivatives as potent anti-HIV and anti-HSV microbicides
PLOS ONE | https://doi.org/10.1371/journal.pone.0198478 June 5, 2018 2 / 19
Competing interests: The commercial affiliation to
Lead Discovery Siena srl does not alter our
adherence to PLOS ONE policies on sharing data
and materials.
trithiocarbonate (7) to form the substituted rhodanine intermediates (8a-f), followed by Knoe-
venagel condensation with aldehyde (6) catalysed by an excess of primary amine (Fig 2).
Antiviral activity and cytotoxicity on TZM-bl cell line infected with HIV-1
laboratory strains
The synthesized compounds (Fig 3) were tested in vitro, together with the parent compounds
1 and 2, to evaluate their ability to inhibit HIV replication on human TZM-bl cells infected
with HIV-1 NL4.3 (CXCR4-tropic strain) or AD8 (CCR5-tropic strain). All compounds
showed antiviral activity at nanomolar concentrations with the parent compound 2 displaying
the best inhibitory profile, having an EC50 of 6.9 nM and 4 nM on AD8 and NL4.3 HIV strains,
respectively. Compound 9a showed a comparable inhibitory effect (7.5 nM and 5.4 nM on
AD8 and NL4.3 HIV strains, respectively) but a worst safety profile with respect to the other
compounds. Indeed, almost all compounds of the series showed low cytotoxicity in TZM-bl
cell line, with CC50 values higher than 20 μM. Only for compound 9a and 9d lower CC50 val-
ues were found (2.2 μM and 12.3 μM, respectively). Interestingly, all compounds displayed a
reduction of antiviral activity when pre-incubation with virus was performed in presence of
complete medium containing fetal bovine serum (FBS). Particularly, the activity of compound
2 against AD8 strain decreased 90 times in presence of serum, shifting from 6.9 nM to 650
nM. Also compound 1 showed a high loss of activity against NL4.3 strain, with an EC50 that
moved from around 50 nM to 3 μM, corresponding to a 64-fold activity reduction.
Fig 1. 2D structures of HIV-1 inhibitors previously published.
https://doi.org/10.1371/journal.pone.0198478.g001
Fig 2. Synthesis of aldehyde 6 and derivatives 9a-f. Synthesis scheme of aldehyde 6: i) Pd(PPh3)2Cl2, Na2CO3, DMF/EtOH, RT, 1h; ii) 1N NaOH
(aq), MeOH/THF, reflux 2h. Synthesis scheme of derivatives 9a-f: iii) DME, Et3N, MW (300 W), 90˚C, 10 min. iv) aldehyde 6, MW (300 W), 110˚C,
5 min.
https://doi.org/10.1371/journal.pone.0198478.g002
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Compounds 9b-f showed moderate to low loss of activity, in the range of 5 to 38 times. Com-
mercially available drugs such as maraviroc [20] and raltegravir [21] did not show any alter-
ation of antiviral activity when pre-incubated with serum.
Antiviral activity and cytotoxicity on human CD4+ lymphocytes
The antiviral activity and cytotoxicity of the most promising compound (2) was evaluated also
on freshly purified human CD4+ cells. CD4+ T lymphocytes were infected with the two refer-
ence laboratory wild type strains NL4.3 and AD8, as well as with two recombinant viruses
bearing mutations of specific integrase residues (Q148H, G140S and Y143R) that confer resis-
tance to raltegravir (RAL). As reported in Table 1, compound 2 was found to be active at low
nanomolar concentrations (11–13 nM) on both NL4.3 and AD8 HIV strains also in CD4+
human lymphocytes, while showing a CC50 of 810 nM and thus a selectivity index of 62. Inter-
estingly, in contrast to raltegravir, compound 2 maintained similar EC50 values also on inte-
grase mutating recombinant viruses, thus suggesting that the strong antiviral activity of the
series of rhodanine derivatives could not be ascribed to integrase inhibition [18].
Antiviral activity and cytotoxicity on Vero cell line infected with HSV-2
laboratory strain and HeLa infected with HPV-16 PsVs
The rhodanine derivatives were also tested in vitro to evaluate their antiviral activity toward
HSV-2 on Vero cells and HPV-16 in HeLa cells. No antiviral activity was shown for all the
compounds up to 50 μM for HPV-16. Instead, the compounds were subjected to a plaque
reduction assay against HSV-2, in which they were pre-incubated with the virus for 1h at
37˚C; then the mixtures were added on cells. As shown in Table 2, all the compounds were
found to be active at nanomolar concentration and showed EC50 values lower than that
obtained for acyclovir, which was used as reference compound. Particularly, the tested rhoda-
nines proved to be up to 130-fold more active than acyclovir (compound 9b) while presenting
a very good safety profile, with selectivity indexes ranging from 600 (9d) to 9400 (2). Com-
pound 2 showed the best HSV-2 antiviral profile, with an EC50 in the low nanomolar range
(11.9 nM) and the highest selectivity index. Therefore, we further investigated the antiviral
activity of this compound on HSV-1 and an acyclovir resistant strain of HSV-2.
Compound 2 was found to be about 10 times less active on HSV-1 with respect to HSV-2
(Table 3). Anyway, this rhodanine derivative showed an EC50 (132 nM) slightly lower than
that obtained for acyclovir (168 nM) and maintained a good safety profile (SI > 752.7). More-
over, compound 2 completely retained its antiviral activity toward the acyclovir resistant strain
Fig 3. Antiviral activity of the novel series of rhodanine derivatives on TZM-bl cell line infected with two laboratory strains (NL4.3 and AD8).
Maraviroc (MAR) and raltegavir (RAL) were used as reference compounds. Values represent mean±S.D of three independent experiments. Differences
between pre-incubation in complete medium containing FBS are shown, together with the corresponding fold change (ratio). EC50 = Half maximal effective
concentration. CC50 = Half maximal cytotoxic concentration.
apre-incubation in complete medium containing fetal bovine serum (FBS).
https://doi.org/10.1371/journal.pone.0198478.g003
Table 1. CC50 and EC50 values of the reference compound 2 and the control drug raltegravir (RAL) on human CD4
+ T lymphocytes.
Compound NL 4.3 WT EC50(nM) AD8 WT EC50(nM) Q148H, G140S EC50(nM) Y143R EC50 (nM) CC50 (nM) SI
2 13±3 11±1 9±2 8±3 810±20 62
RAL 3±2 2±3 800±12 460±10 n.a n.a
SI = Selectivity Index. EC50 = Half maximal effective concentration. CC50 = Half maximal cytotoxic concentration. Values represent mean±S.D of three independent
experiments.
https://doi.org/10.1371/journal.pone.0198478.t001
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of HSV-2, suggesting a different mechanism of action and highlighting the potential of this
series of rhodanines for the treatment of HSV-2 infections resistant to acyclovir. However, as
expected, compound 2 showed a remarkable reduction of HSV-2 inhibitory activity when pre-
incubated with the virus in presence of serum.
Binding to bovine serum albumin in a cellular model
To better elucidate the mechanism underlying the loss of activity observed for the rhodanine
compounds during incubation with complete medium, the selected compound 2 and the con-
trol drug maraviroc were pre-incubated with the AD8 strain of HIV-1 in presence of concen-
trations of FBS ranging from 0% to 10%. As shown in Fig 4, the increase of FBS concentration
from 2% to 10% corresponded to a progressive loss of activity, corroborating the inhibitory
effect of serum on compound 2. Such alteration was not seen on maraviroc, whose antiviral
efficacy did not change with the modification of FBS concentration (data not shown).
To evaluate if the inhibitory effect of serum on compound 2 was due to the binding to
serum albumin, compound 2 and the reference drug maraviroc were pre-incubated with the
virus and increasing concentrations of purified bovine serum albumin (BSA), starting from
the physiological concentration present in the bovine serum up to ten-fold values. A physio-
logical concentration of albumin altered only modestly the antiviral activity of compound 2
(20% loss), when tested at a concentration of 2 μM (Fig 5). However, at a concentration of 400
nM the reduction of compound’s activity was found to be stronger (about 50%) and increasing
Table 2. Antiviral activity of the rhodanine derivatives on Vero cell line infected with HSV-2.
Compound HSV-2 Citotoxicity (Vero cells) SI
EC50 (nM) EC90 (nM) CC50 (μM)
1 168±143 2107±918 224.2±78.5 1134
2 11.9±5.73 481±299 111.9±11.6 9403
9a 345±168 426±56.3 >300 >869
9b 4.89±1.59 57.8±22.6 10.8±.9.50 2209
9c 52.0±21.2 422±225 204.7±30.1 3936
9d 28.7±7.11 140±61.2 16.92±4.31 604.3
9e 50.3±10.5 206±85.5 >100 >1988
9f 26.4±11.1 153±159 7.87±2.98 298
ACV 622±21.1 - 732±46.2 1177
Acyclovir (ACV) was used as reference compound. Values represent mean±S.D of two independent experiments. EC50 = Half maximal effective concentration. EC90 =
90% maximal effective concentration. CC50 = Half maximal cytotoxic concentration. The selectivity index (SI) was calculated by dividing the CC50 by the EC50 value.
https://doi.org/10.1371/journal.pone.0198478.t002
Table 3. Antiviral activity of compound 2 on Vero cell line infected with HSV-1, HSV-2 with serum and HSV-2 acyclovir resistant strains.
Compound Virus EC50 (nM) Vero cell CC50 (μM) SI
2 HSV-1 131±59.9 98±23.1 >752.7
ACV HSV-1 168±41.3 698±72.5 4155
2 HSV-2 with serum 719±157.7 n.d. n.d.
2 HSV-2 acyclovir resistant 10.7±6.34 111.9±11.6 >10,400
ACV HSV-2 acyclovir resistant 31915±1159 732±46.2 22.93
Acyclovir (ACV) was used as reference compound. Values represent mean±S.D of two independent experiments. EC50 = Half maximal effective concentration. CC50 =
Half maximal cytotoxic concentration. The selectivity index (SI) was calculated by dividing the CC50 by the EC50 value.
https://doi.org/10.1371/journal.pone.0198478.t003
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the BSA concentration of 5 to 10 folds led to a complete loss of activity. As expected, the antivi-
ral activity of the control drug maraviroc was not influenced by any concentration of BSA.
Antiviral activity of compound 2 in a microbicide gel formulation
Considered the promising antiviral activity of compound 2 on both HIV-1 and HSV-1/2, as
well as the negative effect of serum on its efficacy, we envisioned that a topical administration
of the compound would have overcome the problem of albumin binding and represented a
suitable strategy for a pre-exposure prophylaxis (PrEP) approach for the treatment of HIV
infection. For this reason we evaluated the activity of compound 2 and the reference com-
pound tenofovir in a microbicide gel formulation using a transwell experiment. The usage of
Fig 4. Effect of different concentrations of fetal bovine serum (0%, 2%, 5% and 10%) on the antiviral activity of
compound 2. Compound 2 was tested in TZM-bl cells infected with AD8 HIV-1 laboratory strain.
https://doi.org/10.1371/journal.pone.0198478.g004
Fig 5. Effect of different concentrations of purified bovine serum albumin on the antiviral activity of compound 2
and maraviroc. Compounds were tested on TZM-bl cells infected with AD8 HIV-1 strain. No BSA = absence of BSA;
1X = 35 mg/mL BSA; 5X = 175 mg/mL BSA; 10X = 350 mg/mL BSA.
https://doi.org/10.1371/journal.pone.0198478.g005
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such experiment allowed to test the compounds in a gel formulation at a high concentration
(50%) for all drug dilutions without affecting cell viability and antiretroviral activity evaluation.
As shown in Fig 6, compound 2 maintained its antiviral activity in the gel formulation, despite
the increase in EC50 observed in the transwell experiment (EC50 of 13 μM), which was however
less than 3-fold higher than that observed for tenofovir (EC50 of 4.5 μM).
In vitro ADME studies
Solubility, permeability and metabolic stability. Selected compounds from the rhoda-
nine series were profiled in vitro for aqueous solubility (thermodynamics solubility), liver
microsomal stability and membrane permeability (Table 4). Although the aqueous solubility
of the compounds (ranging from 0.1 to 0.88 μg/mL) was found to be rather low, this aspect did
not prevent the efficacy of the gel formulation according to the results obtain from solubility
assessment (data not shown). In fact, the concentrations of the compounds in the pre-gel solu-
tions obtained using our experimental conditions were identical to those of the control solu-
tion. In the same way, passive membrane permeability in a PAMPA assay indicated a low
Fig 6. Anti-HIV-1 activity of compound 2 (black line) and tenofovir (T, grey line) in gel, formulation, in human
TZM-bl cell line. Each concentration of both compounds was evaluated in triplicate.
https://doi.org/10.1371/journal.pone.0198478.g006
Table 4. Results of in vitro ADME analysis for selected rhodanine derivatives.
Compound In vitro ADME
Water Solub. (μg/mL) Papp (1·10-6cm/sec) Metabolic Stability (%) Kd HSA (μM) Kd BSA (μM)
1 0.88±0.10 1.28 >90% 0.63±0.1 0.68±0.1
2 0.52±0.13 1.26 >90% 0.96±0.1 0.63±0.1
9a 0.54±0.08 0.4 >90% 1.51±0.2 1.08±0.2
9b 0.10±0.08 2.32 >90% 1.57±0.2 1.55±0.3
9c 0.30±0.07 1.23 >90% 1.19±0.1 1.05±0.1
9d 0.25±0.09 1.50 >90% 1.09±0.9 0.99±0.9
9e 0.72±0.12 0.92 >90% 2.19±1.0 1.07±0.9
9f 0.73±0.14 0.87 >90% 2.23±1.2 1.09±0.9
Values represent mean±S.D of three independent experiments
https://doi.org/10.1371/journal.pone.0198478.t004
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membrane permeability value for all compounds (ranging from 0.4 to 2.32 · 10−6 cm/s). How-
ever, this feature is considered to be drug-like, since it increases the time of exposure of the
microbicide to the site of application, thus increasing its local activity. Moreover, stability tests
disclosed that all compounds showed a good metabolic stability in human liver microsomes
(>90%).
Albumin binding fluorimetric assay. The selected method was first validated with drugs
(paracetamol, diazepam and warfarin) having known Kd for human serum albumin (HSA)
and experimental results were in good agreement with literature data [22] (S1 Table). Each
compound analyzed by fluorimetric titration showed decreased intrinsic fluorescence of Tryp-
tophan and the percentage of bound albumin (HAS and BSA) at different concentrations was
calculated. The percentages obtained were plotted against the concentrations used and the
obtained Kd values are reported in Table 4. Overall, all the compounds showed low Kd values,
demonstrating a high binding affinity to serum albumin. In fact, it is well known that com-
pounds showing Kd values lower than 10 μM are characterized by binding affinity to plasmatic
proteins greater than 90% [22].
Storage Stability of compound 2 Gel Formulation. The sample, at final concentration of
50 μM, was found to be stable at 25˚C stored in the dark. Compound 2 recovery after 1 month
of storage amounted to about 100%. In addition, the apparent viscosity and pH of this gel
remained stable during storage (283.31 ± 8.21 and 7.41 ± 0.08 respectively).
Conclusions
Several studies confirmed the efficacy of topical PrEP approaches to limit the burden of novel
HIV-1 infections and to enhance global efforts to eradicate this virus. However, several co-fac-
tors may limit the efficacy of PrEP approaches. Patients’ compliance due to the need of fre-
quent or fastidious topical applications was initially shown as a critical cause of protection
failure [9,10]. Therefore, the usage of long-acting formulations or slow releasing devices signif-
icantly ameliorated patients’ compliance and PrEP efficacy. Unfortunately, independently
from the type of vehicle and release kinetic of current PrEP formulations, the presence of cir-
culating strains already resistant to available antiretroviral agents (present in the PrEP prepara-
tions) or the co-presence of other genital infections such as those due to HSV-1 or 2, which
increase patient’s susceptibility to HIV-1 infection, remain unsolved problems [11]. During
HSV-1 or 2 infections, the mucosal barrier damage and the increased number of inflammatory
cells susceptible to HIV-1 infection facilitate HIV-1 transmission. Interestingly, despite the
very limited anti HSV-2 activity of tenofovir [16], in the CAPRISA 004 study, TFV PrEP
reduced occurrence of HSV-2 infection by 50%, possibly enhancing the overall observed effi-
cacy against HIV-1. Thus, multipurpose combinations of different compounds with antiviral
and antiretroviral activity are intensively investigated, sometimes also associated with unin-
tended pregnancy prevention compounds [23–28]. Compounds acting on both viruses such as
the rhodanine derivatives described in this paper, represent effective agents to be used in can-
didate PrEP approaches without the need of dual-agents preparations. We demonstrated in
our previous paper that these molecules block very early step in virus replication, preventing
viral entry into cells. The inactivity against HPV-16, a not enveloped virus implicated in sexu-
ally transmitted infections suggests that the viral envelope could be implicated in the mode of
action of our compounds. Preliminary data in our possess corroborate our hypothesis demon-
strating that our compounds act on specific components of the viral envelope. These results
will be reported in a subsequent more specific manuscript. Compounds targeting efficiently
the entry of both HIV-1 or HSV-1 and 2 may represent a very attractive strategy to prevent tar-
get cell infection, with limited cell toxicity and reduced need of tissue penetration.
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Moreover, PrEP devices undergoing clinical trials are based on already available antiretrovi-
ral molecules or their derivatives, thus running the risk of being ineffective to prevent trans-
mission of previously selected drug-resistant strains from the donor patients. In fact, as
expected, mutations which confer resistance to TFV have been reported in oral TFV PrEP reg-
imens [11]. Similar observations may arise in the future in the case of other reverse transcrip-
tase or integrase inhibitors PrEP-based devices, in parallel with the increased usage of
molecules within these drug classes (with cross-resistance profiles) in currently used highly
active antiretroviral therapies (HAART) worldwide, including developing countries. Thus,
molecules with novel mechanisms of action and targeting very early steps of virus life cycle
may represent potent anti-HIV-1 agents able to block the formation of a viral reservoir of
chronically infected cells.
The activity of such inhibitors decreased of several times (from 20 to 100) once they were
pre-incubated with serum before the in vitro assay. To better elucidate this behavior, the bind-
ing affinities of the new derivatives to the Human and Bovine Serum Albumin (HSA/BSA)
were determined by a fluorescence-spectroscopy measurement and the Kd values were esti-
mated. As a result, high affinity binding of the studied molecules to albumin was found, which
could explain the loss of activity observed in vitro in the case of serum or purified recombinant
albumin pre-incubation. Remarkably, the salicylic acid group resulted to be crucial for both
antiviral activity and albumin binding [18]. These pharmacokinetic characteristics, which will
be better explored in the future to modulate a long-acting release or activity of this compound
even for systemic antiretroviral treatments, could be extremely useful to reduce toxicity of
these novel compounds when used in topical preparations. Indeed, high locally active drug
concentrations may be reached (favored also by the drug-like features observed in the ADME
experiments) at the mucosal interface, with a significantly reduced risk of systemic toxicity due
to the rapid albumin binding and inactivation of the compounds.
Materials and methods
Chemistry
General information. All commercially available chemicals were used as purchased.
Anhydrous reactions were run under a positive pressure of dry N2. Thin-layer chromatogra-
phy (TLC) was carried out using Merck TLC plates: silica gel 60 F254. Chromatographic puri-
fications were performed on columns packed with Merck 60 silica gel, 23–400 mesh, for the
flash technique. 1H and 13C NMR spectra were recorded at 400 MHz on a Bruker Avance
DPX400 spectrometer. Melting points were measured using a Gallenkamp melting point appa-
ratus and are uncorrected. Microwave irradiation experiments were conducted using a CEM
Discover Synthesis Unit (CEM Corp., Matthews, NC, USA). The instrument consists of a con-
tinuous focused microwave power delivery system with operator-selectable power output from
0 to 300 W. The temperature of the contents of the vessel was monitored with a calibrated IR
temperature control mounted under the reaction vessel. All experiments were performed
using a stirring option, whereby the contents of the vessel are stirred by a rotating magnetic
plate located below the floor of the microwave cavity and a teflon-coated magnetic stir bar in
the vessel.
Methyl 4-(5-formylfuran-2-yl)-2-hydroxybenzoate (5). Methyl-4-iodosalycilate 3 (1.00
mmol) and 5-formyl-2- furan boronic acid 4 were dissolved in 10 mL of DMF and 15 mL of
EtOH. The reaction mixture was stirred for 10 minutes under N2, then Pd(PPh3)2 Cl2 (0.10
mmol) was added and finally Na2CO3 2M (6.00 mmol). The reaction mixture (light-orange)
was stirred under N2 at room temperature. After 1h the reaction went to completion (monitor-
ing with TLC) and was quenched with H2O and 2N HCl, then EtOAc was added, and the
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mixture was stirred until the two layers became clear. The aqueous layer was extracted three
times with EtOAc, then the organic phase were washed several times with H2O and brine,
dried over Na2SO4, filtered and evaporated under reduced pressure. The crude product was
purified by flash chromatography using PE/EtOAc = 4:1 as eluent to yield the wishes product
5 as a light orange solid (yield: 96%); mp = 150˚C (decomposition); 1H NMR (CDCl3, 400
MHz): ð = 10.84 (s, 1H), 9.69 (s, 1H), 7.91–7.88 (d, 1H, J = 12 Hz), 7.40–7.39 (d, 1H, J = 4 Hz),
7.35–7.32 (m, 3H), 6.94–6.93 (d, 1H, J = 4Hz), 3.97 (s, 3H); 13C (CDCl3, 100 MHz): ð = 177.47,
161.69, 157.37, 152.53, 135.17, 130.58,122.56, 115.74, 113.73, 112.82, 109.84, 52.40, 29.59; MS
(ES): m/z 245.0 [M-H]-; Anal. (C13H10O5) C, H, N.
4-(5-Formylfuran-2-yl)-2-hydroxybenzoic acid (6). Compound 5 was dissolved in 25
mL of CH3OH, then a solution of NaOH 1M (5.00 mmol) was added dropwise, after the reac-
tion mixture was heated at reflux. The reaction mixture was stirred overnight until completion
(TLC). Organic solvent was removed under reduced pressure, then some water was added,
and the aqueous layer was extracted three times with Et2O; the aqueous layer was then acidi-
fied to pH 1 with HCl 6N and a precipitated appeared. (6) was obtained as a brown-red solid
(yield: 95%); mp = 230˚C (decomposition); 1H NMR (DMSO, 400 MHz): ð = 9.63 (s, 1H),
7.88–7.86 (d, 1H, J = 8 Hz), 7.66–7.65 (d, 1H, J = 4 Hz), 7.45–7.39 (m, 3H); 13C NMR (DMSO,
100 MHz): ð = 178.72, 171.68, 161.69, 156.82, 152.63, 135.11, 131.72, 125.14, 116.02, 114.06,
113.29, 111.53; MS (ES): m/z 231.0 [M-H].
General Procedure for the synthesis of final compounds 9a-f. To a solution of bis(car-
boxymethyl)trithiocarbonate (0.22 mmol) in DME (1.0 mL) were added TEA (0.22 mmol) and
the opportune amine (0.22 mmol). The reaction mixture was heated at 90˚C for 10 min under
microwave irradiation. After this time, the aldehyde 6 (0.22 mmol) was added, and the mixture
was heated at 110˚C for 5 min under microwave irradiation. The reaction mixture was evapo-
rated to dryness and the residue was additioned with MeOH and a drop of HCl 2N; the final
rhodanine derivatives were obtained as a pure precipitate, isolated by filtration, washed with
water and hexane, and finally dried under high vacuum.
(Z)-4-(5-((3-(4-fluorophenethyl)-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-
2-yl)-2-hydroxybenzoic acid (9a). (yield: 30%); Yellow solid. Mp = 292˚C (decomposition),
1H NMR: (400 MHz, DMSO-d6) d = 7.92–7.90 (d, 1H, J = 8.0 Hz), 7.61 (s, 1H), 7.42–7.41 (d,
1H, J = 3.2 Hz), 7.38–7.33 (m, 3H),7.26–7.22 (m, 2H), 7.11–7.06 (m, 2H), 4.26.4.22 (m, 2H),
2.99–2.95 (m, 2H) ppm. 13C NMR (100 MHz, DMSO-d6): d = 194.20, 171.72,166.65, 161.84,
156.71, 154.49, 150.43, 134.83, 134.20, 131.78, 131.00,130.91, 123.19, 119.91, 118.46, 116.16,
115.72, 115.51, 113.76, 113.04,112.41, 45.63, 31.68 ppm. MS (ES): m/z 468.0 [M-H]-. HPLC:
tr = 4.58 min; conditions: temp = 25˚C, mobile phase composed of (A)70% acetonitrile and
(B) 30% water with 0.5% formic acid at a flowrate of 1.0 mL/min; purity: 96.5%.
(Z)-2-hydroxy-4-(5-((3-(4-methylphenethyl)-4-oxo-2-thioxothiazolidin-5-ylidene)
methyl)furan-2-yl)benzoic acid (9b). (yield: 79%); Orange solid. Mp = 258˚C (decomposi-
tion);1H NMR: (400 MHz DMSO-d6) d = 7.91–7.89 (d, 1H, J = 8.0 Hz), 7.60 (s, 1H), 7.42–7.33
(m, 4H), 7.10–7.08 (m, 4H), 4.21–4.18 (m, 2H), 2.92–2.88 (m, 2H), 2.25 (s, 3H) ppm. 13C
NMR (100 MHz, DMSO-d6): d = 194.03, 178.56, 171.56, 166.68, 161.84, 156.79, 150.52, 135.99,
134.93, 131.77, 129.44, 128.88, 122.95, 120.15, 118.36, 115.56, 114.37, 113.86, 112.91, 112.52,
11.32, 45.70, 32.16, 20.96 ppm. MS (ES): m/z 464.0 [M-H]-. HPLC: tr = 4.65 min; conditions:
temp = 25˚C, mobile phase composed of (A) 70% acetonitrile and (B) 30% water with 0.5%
formic acid at a flow rate of 1.0 mL/min; purity:95.9%.
(Z)-2-hydroxy-4-(5-((4-oxo-3-(3-phenylpropyl)-2-thioxothiazolidin-5-ylidene)methyl)
furan-2-yl)benzoic acid (9c). (yield: 91%); Orange solid. Mp = 248˚C (decomposition);
1HNMR: (400 MHz, DMSO-d6) d = 7.90–7.88 (d, 1H, J = 8.4 Hz), 7.61 (s,1H), 7.44–7.43 (d,
1H, J = 4.0 Hz), 7.36–7.32 (m, 2H), 7.28–7.14 (m, 5H), 4.04–4.01 (m, 2H), 2.66–2.62 (m, 2H),
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1.98–1.92 (m, 2H) ppm. 13C NMR (100 MHz, DMSO-d6): d = 194.23, 171.74, 166.91, 161.79,
156.60, 150.53, 141.20, 134.94, 131.77, 128.68, 128.55, 126.30, 122.99, 120.28, 118.28, 115.53,
113.49, 113.06, 112.39, 44.39, 32.72, 28.16 ppm. MS (ES): m/z 464.0 [M-1]-. HPLC: tr = 4.36
min; conditions: temp = 25˚C, mobile phase composed of (A) 70% acetonitrile and (B) 30%
water with 0,5% formic acid at a flow rate of 1.0 mL/min; purity: 96.8%.
(Z)-4-(5-((3-(4-ethylphenethyl)-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-
2-yl)-2-hydroxybenzoic acid (9d). (yield: 80%); Brown solid. Mp = 273˚C (decomposi-
tion);1H NMR: (400 MHz, DMSO-d6) d = 7.89–7.87 (d, 1H, J = 8.0 Hz), 7.58 (s, 1H), 7.42–7.41
(d, 1H, J = 3.6 Hz), 7.34–7.30 (m, 2H), 7.12–7.11 (m, 5H), 4.18–4.14 (m, 2H), 2.90–2.86 (m,
2H), 2.57–2.52 (q, 2H, J = 7.6 Hz), 1.15–1.11 (t, 3H, J = 7.6 Hz) ppm. 13C NMR (DMSO-d6100
MHz): d = 193.44, 171.74, 166.58, 161.80, 156.66, 150.42, 149.51, 142.40, 135.13, 134.85,
131.71, 128.92, 128.28, 123.10, 119.97, 118.35,115.49, 113.54, 113.01, 112.39, 45.69, 32.16,
28.16, 15.98 ppm. MS (ES): m/z 478.0 [M-H]-. HPLC: tr = 4.23 min; conditions: temp = 25˚C,
mobile phase composed of (A) 70% acetonitrile and (B) 30% water with 0.5% formic acid at a
flow rate of 1.0 mL/min; purity:96.5%.
(Z)-4-(5-((3-(3-chloro-4-fluorophenyl)-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)
furan-2-yl)-2-hydroxybenzoic acid (9e). (yield 30%) red solid, 1H NMR (400 MHz, DMSO-
d6) δ11.32 (s, 1H), 7.89 (d, J = 8.1 Hz, 1H), 7.77 (d, J = 6.4 Hz, 1H), 7.68 (s, 1H), 7.62 (t, J = 8.9
Hz, 1H), 7.54–7.47 (m, 1H), 7.43 (d, J = 3.3 Hz, 1H), 7.36–7.32 (m,3H)ppm; 13C NMR
(DMSO-d6100 MHz): δ 198.0, 171.60, 167.62, 156.59, 155.80, 152.63, 152.07, 135.06, 134.53,
129.32, 126.76, 125.48, 124.06, 122.43, 120.60, 117.57, 115.92, 115.62, 111.62, 111.29,
103.95 ppm MS (ES): m/z 474.0 [M-H]-. HPLC: tr = 4.61 min; conditions: temp = 25˚C,
mobile phase composed of (A) 70% acetonitrile and (B) 30% water with 0,5% formic acid at a
flow rate of 1.0 mL/min; purity:97.1%.
(Z)-4-(5-((3-(4-chloro-3-fluorobenzyl)-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)
furan-2-yl)-2-hydroxybenzoic acid (9f). (yield 57%) brown solid, 1H NMR (400 MHz,
DMSO-d6) δ 11.28 (s, 1H), 7.85 (d, J = 8.0 Hz, 1H), 7.62 (s, 1H), 7.52 (t, J = 7.8 Hz, 1H), 7.39 (s,
1H), 7.36–7.24 (m, 3H), 7.15 (d, J = 8.0 Hz, 1H), 5.18 (s, 2H)ppm, 13C NMR (101 MHz,
DMSO-d6) δ 204.26, 181.73, 176.87, 171.78, 168.65, 166.82, 165.98, 160.40, 146.86, 144.67,
141.68, 140.82, 135.19, 133.36, 129.92, 129.20, 128.86, 126.69, 126.19, 125.22, 123.56, 123.03,
122.07, 56.51ppm. MS (ES): m/z 488.0 [M-H]-. HPLC: tr = 4.28 min; conditions: temp = 25˚C,
mobile phase composed of (A) 70% acetonitrile and (B) 30% water with 0.5% formic acid at a
flow rate of 1.0 mL/min; purity:96.6%.
Antiviral activity and cell toxicity
Phenotypic analyses with fully replicating recombinant HIV-1 strains and clonal viral
variants selected in patients failing integrase inhibitors on TZM-bl cells and human CD4+
lymphocyte. The human TZM-bl indicator cell line (obtained from the NIH AIDS reagents
program, cat. Nr 8129 (www.aidsreagent.org) and maintained at 37˚C and 5% CO2 in Dulbec-
co’s modified Eagle’s medium (DMEM) medium containing 10% fetal bovine serum, 50 μg/
mL penicillin, and 50 μg/mL streptomycin. The HIV-1 laboratory strains NL(AD8) (NIH
AIDS reagents program, cat.nr 11346), NL4.3 (NIH AIDS reagents program, cat. Nr. 114)
were titrated as previously reported. Briefly, serial 5-fold dilutions of each virus were made in
quadruplicate wells in 96-well culture plates, in a total volume of 100 μL of growth medium
(DMEM), for a total of 8 dilution steps. Freshly trypsinized cells (20,000 cells in 100 μL of
growth medium containing 75 μg/mL DEAE-dextran) were added to each well, and the plates
were incubated at 37˚C in a humidified 5% CO2-95% air environment. After 48 h of incuba-
tion, the medium was removed and viral infection was quantified using a β-galactosidase
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(CPRG) assay (Roche). Twenty thousand TZM-bl cells/well were seeded in 96-well plates in
complete DMEM supplemented with 30 μg/mL DEAE-dextran (Sigma-Aldrich). Three hun-
dred times the 50% tissue culture infective dose (TCID50)/mL of each strain was pretreated for
1 h at 37˚C with six serial dilutions (20000 nM to 3.2 nM) of each compound and then added to
the cells, as previously described [29–32]. Vehicle (0.1% dimethyl sulfoxide [DMSO])-treated
cells served as a negative control. A CCR5 inhibitor (maraviroc) and an integrase inhibitor (ral-
tegravir) were used as positive-control drugs. After 2 days, viral infection was quantified using a
CPRG assay (Roche). The inhibitory curves were fitted by nonlinear regression, allowing for the
calculation of the 50% inhibitory concentration (IC50) using the Prism software. To evaluate the
cell toxicity of the compounds, the metabolic XTT [2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-
2H-tetrazolium-5-carboxanilide] test (Sigma-Aldrich) was performed according to the manu-
facturer’s instructions.
The antiviral activity and cytotoxicity of compounds 2, 9e and 9f was tested also on freshly
purified human CD4+ T lymphocytes obtained from healthy blood donors (informed consent
available) as described previously on HIV laboratory strain NL4.3 and AD8 [33,34].
HSV-1 and HSV-2 antiviral activity in vero cells. African green monkey fibroblastoid
kidney cells (Vero, ATCC CCL-81) were grown as monolayers in Eagle’s minimal essential
medium (MEM) (Gibco/BRL, Gaithersburg, MD) supplemented with 10% heat inactivated
fetal calf serum (FCS) and 1% antibiotic-antimycotic solution (Zell Shield, Minerva Biolabs
GmbH, Berlin, Germany).
Clinical isolates of HSV-1 and HSV-2 were kindly provided by Prof. M. Pistello, University
of Pisa, Italy. HSV-1 and HSV-2 strains were propagated and titrated by plaque assay on Vero
cells. A HSV-2 strain with phenotypic resistance to acyclovir was generated by serial passage in
the presence of increasing concentrations of acyclovir, as previously described [35].
Acyclovir was purchased from Sigma Aldrich (Milan, Italy).
The effect of the rhodanine derivatives on HSV infection was evaluated by plaque reduction
assay. Vero cells were pre-plated 24 h in advance in 24-well plates at a density of 105 cells.
Increasing concentrations of compounds were mixed with HSV-2 (MOI 0.001 pfu/cell) or
HSV-2 acyclovir resistant (MOI 0.001) or HSV-1 (MOI 0.0005) or and incubated for 1 hour at
37˚C. The mixtures were subsequently added to the cells, which were then incubated at 37˚C
for 2 h. The virus inoculum was then removed and the cells washed and overlaid with a
medium containing 1.2% methylcellulose (Sigma). After further incubation at 37˚C for 24 h
(HSV-2 and HSV-2 R Acy) or 48 h (HSV-1), cells were fixed and stained with 0.1% crystal vio-
let in 20% ethanol and viral plaques counted. The effective concentration producing 50%
reduction (EC50) and 90% reduction (EC90) in plaque formation was determined using Prism
software by comparing drug-treated with wells treated with medium and solvent. The selectiv-
ity index (SI) was calculated by dividing the CC50 by the EC50 value.
All results are presented as the mean values from three independent experiments. The EC50
values for inhibition curves were calculated by regression analysis using the software Graph-
Pad Prism (GraphPad Software, San Diego, California, U.S.A.) by fitting a variable slope-sig-
moidal dose–response curve. Acyclovir was purchased from Sigma Aldrich (Milan, Italy).
Vero cell viability. Cell viability was measured using the MTS [3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay. Cell cultures
were seeded in 96-well plates were incubated with different concentrations of compounds in
triplicate under the same experimental conditions described for the antiviral assays. Cell viabil-
ity was determined using the CellTiter 96 Proliferation Assay Kit (Promega, Madison, WI,
USA) according to the manufacturer’s instructions. Absorbances were measured using a
Microplate Reader (Model 680, BIORAD) at 490 nm. The effect on cell viability at different
concentrations of the compound was expressed as a percentage, by comparing absorbances of
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treated cells with those of cells incubated with culture medium and equal volumes of vehicle.
The 50% cytotoxic concentrations (CC50) and 95% confidence intervals (CIs) were determined
using Prism software (Graph-Pad Software, San Diego, CA).
Human papilloma pseudovirus (HPV16 PsV) production
Plasmids and 293TT cells used for pseudovirus (PsV) production were kindly provided by
John Schiller (National Cancer Institute, Bethesda, MD). 293TT cell line, derived from human
embryonic kidney cells transformed with the simian virus 40 (SV40) large T antigen, was cul-
tured in DMEM (Gibco-BRL, Gaithersburg, MD) supplemented with heat inactivated 10%
FCS (Gibco- BRL), Glutamax-I 1% (Invitrogen, Carlsbad, CA) and nonessential amino acids
1% (Sigma Aldrich, Steinheim, Germany). HPV-16 PsVs were produced as described in
Cagno et al 2015. 293TT cells were transfected with plasmid expressing the papillomavirus
major and minor capsid proteins (L1 and L2, respectively), together with a reporter plasmid
expressing GFP. Capsids were allowed to mature overnight in cell lysate; the clarified superna-
tant was then loaded on top of a density gradient of 27 to 33 to 39% Optiprep at room tempera-
ture for 3 h. The material was centrifuged at 28000 rpm for 16 h at 4˚C in an SW41.1 rotor
(Beckman Coulter, Inc., Fullerton, CA) and then collected by bottom puncture of the tubes.
Fractions were inspected for purity in 10% sodium dodecyl sulfate (SDS)–Tris–glycine gels,
titrated on 293TT cells to test for infectivity by GFP detection, and then pooled and frozen at
-80˚C until needed. The L1 protein content of PsV stocks was determined by comparison with
bovine serum albumin standards in Coomassie-stained SDS-polyacrylamide gels.
HPV-16 inhibition assay in HeLa cells
HeLa, Human Adenocarcinoma cells purchased from ATCC CCL-2, were cultured with
DMEM (Gibco-BRL, Gaithersburg, MD) supplemented with heat inactivated 10% FCS
(Gibco- BRL), Glutamax-I 1% (Invitrogen, Carlsbad, CA). Compounds were serially diluted
and incubated with HPV-16 (MOI 0.1) for 1 h at 37˚C. Then the mixture was added to 8E4
HeLa cells grown as monolayers in a 96-well plate. Three days post-infection, cells were
observed with a confocal microscope Zeiss LSM 510 and positive cells were counted.
Inhibition of antiviral activity by fetal bovine serum. To evaluate the binding of com-
pounds to plasma proteins also in a cell based assay, the infection with the HIV laboratory
strain AD8 was performed in absence or in presence of different concentrations of Fetal
Bovine Serum (FBS): 2%, 5% and 10%. The representative compound 2 was pre-incubated at
different concentrations ranging from 10 μM to 3.2 nM with 300 TCID50 /mL of AD8 in
DMEM supplemented with 50 μg/mL penicillin, 50 μg/mL streptomycin, 30 μg/mL DEAE-
dextran and FBS at the concentration described above. Maraviroc was used as control. After
an hour the mixture was added to 40.000 TZM-bl cells/well plated in a 96-well plate and after
two days the infection was quantified using a CPRG assay (Roche) as previously described.
Inhibition of antiviral activity by purified bovine serum albumin. To confirm the bind-
ing of compound 2 to serum albumin, infection was performed in presence of different con-
centrations of purified bovine serum albumin (BSA, Sigma Aldrich) starting from the
concentration that is usually present in FBS serum (35 mg/mL, 1X) and increasing to a five-
fold concentration (175 mg/mL) up to a ten-fold concentration (350 mg/mL). In this experi-
ment the pre-incubation between HIV and two selected concentrations of compound 2 and
maraviroc (2000 nM and 400 nM) was performed in DMEM without FBS and supplemented
with BSA at the concentrations described above. After one hour, the mixture was added to
40.000 TZM-bl cells/well plated in DMEM supplemented with 50 μg/mL penicillin, 50 μg/mL
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streptomycin, 30 μg/mL DEAE-dextran and 10% FBS in a 96-well plate. After two days the
infection was evaluated through a CPRG assay.
ADME assay
Chemicals and excipients. All solvents, L-α-phosphatidylcholine, hydroxyethylcellulose
(HEC), and propionic acid were from reagents, were from Sigma-Aldrich Srl (Milan,Italy).
Dodecane was purchased from Fluka (Milan, Italy). Pooled Male Donors 20 mg/mL HLM
were from BD Gentest-Biosciences (San Jose, California). Milli-Q quality water (Millipore,
Milford, MA, USA) was used. Hydrophobic filter plates (MultiScreen-IP, Clear Plates, 0.45 μm
diameter pore size), 96-well microplates, and 96-well UV-transparent microplates were
obtained from Millipore (Bedford, MA, USA).
UV/HPLC-MS method. LC analyses were performed by Agilent 1100 LC/MSD VL sys-
tem (G1946C) (Agilent Technologies, Palo Alto, CA) constituted by a vacuum solvent degas-
sing unit, a binary high-pressure gradient pump, an 1100 series UV detector and a 1100 MSD
model VL benchtop mass spectrometer was used. The Agilent 1100 series mass spectra detec-
tion (MSD) single-quadrupole instrument was equipped with the orthogonal spray API-ES
(Agilent Technologies, Palo Alto, CA). Nitrogen was used as nebulizing and drying gas. The
pressure of the nebulizing gas, the flow of the drying gas, the capillary voltage, the fragmentor
voltage and the vaporization temperature were set at 40 psi, 9 L/min, 3000 V, 70 V and 350˚C,
respectively. UV detection was monitored at 254 nm. The LC-ESI-MS determination was per-
formed by operating the MSD in the negative ion mode. Spectra were acquired over the scan
range m/z 50–1500 using a step size of 0.1 u. Chromatographic analysis was performed using a
Kinetex EVO C18 100A column (150 x 4.6 mm, 5 μm particle size) at room temperature. Anal-
ysis was carried out using a gradient elution of acetonitrile (ACN) and an aqueous solution
(HCOOH 0.1%v/v): t = 0min ACN 5%, t = 3min ACN 5%, t = 12min ACN 95%, t = 25 min
ACN 95%. The analysis was performed at flow rate of 0.6 mL/min and injection volume was
20 μL.
Aqueous solubility. Each solid compound (1 mg) was added to 1 mL of water. Each sam-
ple was mixed at 20˚C, in a shaker water bath for 24 h. The resulting suspension was filtered
through a 0.45 μm nylon filter (Acrodisc). The concentration of solubilized compounds weres
determined by UV/LC-MS (performed in triplicate) by comparison with the appropriate cali-
bration curve that was obtained from samples of the compound dissolved in methanol at dif-
ferent concentrations.
Parallel Artificial Membrane Permeability Assay (PAMPA). Donor solution (0.5 mM)
was prepared by diluting 1 mM dimethylsulfoxide (DMSO) compound stock solution using
phosphate buffer (pH 7.4, 0.025 M). Filters were coated with 5 μL of a 1% (w/v) dodecane solu-
tion of L-α-phosphatidylcholine. Donor solution (150 μL) was added to each well of the filter
plate. To each well of the acceptor plate were added 300 μL of solution (50% DMSO in phos-
phate buffer). All compounds were tested in three different plates on different days. The sand-
wich was incubated for 5 h at room temperature under gentle shaking. After the incubation
time, the plates were separated, and samples were taken from both receiver and donor sides
and analyzed using UV/HPLC-MS gradient method above reported. Permeability (Papp) for
PAMPA, were calculated according to the following equation, obtained from Wohnsland and
Faller [36] and Sugano [37] equation with some modification in order to obtain permeability
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where VA is the volume in the acceptor well, VD is the volume in the donor well (cm
3), A is the
“effective area” of the membrane (cm2), t is the incubation time (s) and r the ratio between
drug concentration in the acceptor and equilibrium concentration of the drug in the total vol-
ume (VD+VA). Drug concentration is estimated by using the peak area integration.
Metabolic stability in HLM (Human Liver Microsomes). The incubation mixture (total
volume of 500 μL) was constituted by the following components: HLM (0.2 mg/mL), a
NADPH regenerating system (NADPH 0.2 mM, NADPH+ 1 mM, D-glucose-6-phosphate 4
mM, 4 unit/mL glucose-6-phosphate dehydrogenase and MgCl2 48 mM), 50 μM of each com-
pound in DMSO and phosphate buffer (pH 7.4, 25 mM, up to a final volume of 500 μL). The
mixture was incubated at 37˚C for 1 h. The reaction was cooled down and quenched with ace-
tonitrile (1.0 mL). After centrifugation (4000 rpm, 10 min), the supernatant was taken, dried
under nitrogen flow, suspended in 100 μL of methanol and analyzed by UV/LC-MS to deter-
mine the percentage of compound that was not metabolized.
Solubility assessment. The solubilizing capacity of formulation media was measured in
the presence of 2% v/v of DMSO. Stock solution of compound 2 and tenofovir, were added to
obtain a final concentration of 50, 25 and 10 μM in the final volume of 1 mL of buffer solution
(pH 7.4 25 mM). After sonication, the samples were shacked in a shaker bath at room tempera-
ture for 24 h to reach equilibrium conditions. Each pre-gel solution was analyzed before and
after filtration by a 0.45-μm nylon filter (Acrodisc). The solubilized compound was deter-
mined using LC-UV-MS method above reported.
Gel formulation. All the semi-solid formulations were prepared adding at the pre-gel
solution reported above hydroxyethyl cellulose (HEC) (1.8% w/v). In all samples, 0.2% v/v pro-
pionic acid was added to aqueous solution in order to preserve form bacteria and mold con-
tamination. HEC was dispersed in the pre-gel solution at 25˚C under magnetic stirring,
overnight.
Storage stability and rheological characterization. Gel containing compound 2 was
stored at 25˚C in the dark. At predetermined data points, the formulations were visually
inspected to evidence aggregate formations and the pH was measured. Rheological evaluations
were performed using a rotational viscometer (Bohlin Model Visco 88, Bohlin Instruments,
UK). Appropriate measuring spindles (C14 DIN) were used during viscosity measurements.
Samples were loaded into the cup and allowed to equilibrate for 10 min at desired temperature
(25 ± 0.5˚C) and apparent viscosity (mPa s) was determined using a shear rate of 552 s-1 over a
1 month period.
Binding fluorimetric assay. The binding of each compounds to HSA (human serum albu-
min) and BSA (bovine serum albumin) were monitored by fluorescence spectroscopy in order
to determine the dissociation constant (Kd). A quantitative analysis of the potential interaction
was performed by fluorimetric analysis using 96 multiwell plates: in each well a fixed concentra-
tion of HSA or BSA (10μM in phosphate buffer 1 mM), was added with different amounts of
tested compound (0.1μM to 500μM by stock solutions in DMSO). Plates were gently shacked
and after allowing 30 minutes at room temperature for equilibration, after excitation at 295nm,
spectra were recorded from 300 to 400 nm with a Perkin Elmer EnVision Multilabel Reader
2014 spectrofluorimeter, spectra were acquired with EnVision Manager ver.1.13 software. The
obtained fluorescence quenching percentages were plotted against drug concentrations and the
relative Kd values were obtained using GraphPad software (version 6.0).
Antiviral activity of compound 2 in a gel formulation
Antiviral activity of compound 2 on NL4.3 HIV strain was evaluated also in a gel formulation.
To reproduce more physiological conditions, TZM-bl cells were seeded into transwells and the
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gel was applied onto the cell monolayer at 50% fixed concentration with serial drug dilutions
as previously described. Briefly, 4x104 TZM-bl cells were plated into each transwell apical
chamber of a 24-well plate (pore size 3μm and diameter 6,5 mm, Corning) containing medium
in the bottom plate and cultured overnight. For efficacy testing, 60 TCID50 of virus was added
to each apical well in the presence of 100 μL of compound 2 gel, tenofovir gel or blank gel at
the final drug concentrations of 25μM, 10 μM and 5 μM. Inhibition of infection was deter-
mined as previously based on deviations from blank gel.
Supporting information
S1 Table. Binding studies realized to validate the used fluorimetric assay.
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